Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in STRASBOURG, Alsace – page 44

977 clinical trials in STRASBOURG, Alsace, France across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
STRASBOURG, Alsace at a glance
977
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

977 trials in STRASBOURG, Alsace

Open in trial search

Prostate cancer

Not yet recruiting

Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:64CU-PSMA I&T
  • Sponsor:Curium US LLC

Abortion threatened

Not yet recruiting

Study on Antibiotic Combination of Ceftriaxone, Clarithromycin, and Metronidazole for Pregnant Women with Threatened Miscarriage and Intact Membranes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ceftriaxone Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Systemic scleroderma

Not yet recruiting

Study comparing rapcabtagene autoleucel and rituximab in patients with severe refractory diffuse cutaneous systemic sclerosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Neoplasm

Not yet recruiting

Study of Spartalizumab and Pazopanib for Patients with Refractory or Recurrent Solid Tumors

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pazopanib
  • Sponsor:Centre Hospitalier Universitaire De Bordeaux

Narcolepsy

Not yet recruiting

Study on TAK-861 for Treating Narcolepsy with Cataplexy in Patients

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N-{(2S,3R)-4,4-Difluoro-1-(2-Hydroxy-2-Methylpropanoyl)-2-[(2,3',5'-Trifluoro[1,1'-Biphenyl]-3-Yl)Methyl]Pyrrolidin-3-Yl}Ethanesulfonamide
  • Sponsor:Takeda Development Center Americas Inc.

Plasma cell myeloma

Not yet recruiting

Study of ixazomib, iberdomide and dexamethasone combination in elderly patients with first relapse of multiple myeloma

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Dexamethasone
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Implantation complication

Not yet recruiting

Study on Certolizumab for Women with Unexplained Recurrent Implantation Failure

Registered drug
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Certolizumab Pegol
  • Sponsor:Assistance Publique Hopitaux De Paris

Plasma cell myeloma

Not yet recruiting

Study on Multiple Myeloma Treatment with Isatuximab, Lenalidomide, and Carfilzomib for Patients Under 66 Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:Intergroupe Francophone Du Myelome

Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

Endometrial cancer

Not yet recruiting

Study Comparing Chemotherapy Alone to Dostarlimab, Paclitaxel, and Carboplatin for Patients with Advanced or Metastatic Endometrial Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Carboplatin
  • Sponsor:Arcagy Gineco

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in STRASBOURG, Alsace

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on head and neck cancers, bladder cancer, and multiple myeloma. Novel therapeutic approaches combining immunotherapy with established treatments are being evaluated for improved patient outcomes.

  • EGFR-targeted therapies for head and neck cancer
  • Non-muscle invasive bladder cancer treatment
  • Multiple myeloma consolidation therapy

Innovative combination therapies are being tested to enhance treatment efficacy while maintaining patient safety.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, essential tremor, and ADHD. Studies are evaluating both new and existing medications for improved symptom management and disease control.

  • Multiple sclerosis treatment strategies
  • Essential tremor therapeutic interventions
  • ADHD neural mechanism studies

Advanced neuroimaging techniques are being utilized to understand treatment effects on brain circuits.

03 Autoimmune Conditions

Investigating new treatments for Crohn's disease, Sjögren's Syndrome, and Myasthenia Gravis. Research focuses on innovative therapeutic approaches including microbiota transplantation and targeted immunotherapies.

  • Fecal microbiota transplantation studies
  • Novel antibody treatments
  • Immunomodulatory therapies

These trials aim to improve disease management and patient quality of life through targeted interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.